Skip to main content
Erschienen in: Annals of Hematology 9/2018

19.04.2018 | Original Article

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

verfasst von: Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Massimiliano Bonifacio, Domenica Gangemi, Federica Sorà, Alessandra Iurlo, Luigiana Luciano, Antonella Gozzini, Massimo Gentile, Monica Bocchia, Debora Luzi, Alessandro Maggi, Nicola Sgherza, Alessandro Isidori, Monica Crugnola, Patrizia Pregno, Anna Rita Scortechini, Isabella Capodanno, Michele Pizzuti, Robin Foà

Erschienen in: Annals of Hematology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32–72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.
Literatur
1.
Zurück zum Zitat Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Engl J Med 369:1783–1796CrossRefPubMed Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Engl J Med 369:1783–1796CrossRefPubMed
2.
Zurück zum Zitat Cortes JE, Kim DW, Pinilla-Ibarz J, et al (2014) Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 124: abstract 3135 Cortes JE, Kim DW, Pinilla-Ibarz J, et al (2014) Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 124: abstract 3135
3.
Zurück zum Zitat Poch Martell M, Sibai H, Deotare U, Lipton JH (2016) Ponatinib in the therapy of chronic myeloid leukemia. Exp Rev Hematol 9:923–932CrossRef Poch Martell M, Sibai H, Deotare U, Lipton JH (2016) Ponatinib in the therapy of chronic myeloid leukemia. Exp Rev Hematol 9:923–932CrossRef
4.
Zurück zum Zitat Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M (2017) Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion. Ann Hematol 96:549–558CrossRefPubMed Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M (2017) Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion. Ann Hematol 96:549–558CrossRefPubMed
5.
Zurück zum Zitat Muller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G (2017) Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol 120:52–59CrossRefPubMed Muller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G (2017) Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol 120:52–59CrossRefPubMed
6.
Zurück zum Zitat Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G (2016) Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. Haematologica 101:e267–e268CrossRefPubMedPubMedCentral Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G (2016) Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. Haematologica 101:e267–e268CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J (2015) Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica 100(suppl 1):e495 Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J (2015) Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica 100(suppl 1):e495
8.
Zurück zum Zitat Hochhaus A, Pinilla-Ibarz J, Kim DW, et al (2014) Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. J Clin Oncol 32(15, suppl): abstract 708 Hochhaus A, Pinilla-Ibarz J, Kim DW, et al (2014) Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. J Clin Oncol 32(15, suppl): abstract 708
Metadaten
Titel
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
verfasst von
Massimo Breccia
Elisabetta Abruzzese
Fausto Castagnetti
Massimiliano Bonifacio
Domenica Gangemi
Federica Sorà
Alessandra Iurlo
Luigiana Luciano
Antonella Gozzini
Massimo Gentile
Monica Bocchia
Debora Luzi
Alessandro Maggi
Nicola Sgherza
Alessandro Isidori
Monica Crugnola
Patrizia Pregno
Anna Rita Scortechini
Isabella Capodanno
Michele Pizzuti
Robin Foà
Publikationsdatum
19.04.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3337-2

Weitere Artikel der Ausgabe 9/2018

Annals of Hematology 9/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.